資料載入中.....
|
請使用永久網址來引用或連結此文件:
https://ir.cnu.edu.tw/handle/310902800/34871
|
| 標題: | Case report: Heterogenous SMARCA4-deficient thoracic non-small cell lung carcinoma with various responses to nivolumab |
| 作者: | Lin, Yun-Tzu
Li, Chien-Feng
Wu, Hung-Chang
Jan, Yi-Hua
Kuo, Yu-Hsuan |
| 貢獻者: | Chi Mei Med Ctr, Dept Oncol
Chi Mei Med Ctr, Dept Pathol
Natl Sun Yat sen Univ, Inst Precis Med
Chi Mei Med Ctr, Dept Med Res
Natl Inst Canc Res, Natl Hlth Res Inst
Chia Nan Univ, Coll Pharm & Sci
ACT Genom Co Ltd
Institute of Biomedical Sciences, National Sun Yat-sen University |
| 關鍵字: | SMARCA4
BRG1
SWI
SNF
lung cancer
non-small cell lung carcinoma
check-point inhibitors
nivolumab |
| 日期: | 2023 |
| 上傳時間: | 2024-12-25 11:04:52 (UTC+8) |
| 出版者: | FRONTIERS MEDIA SA |
| 摘要: | SMARCA4-deficient non-small cell carcinoma is an aggressive neoplasm with poor outcome. Several studies have highlighted its immunochemistry, pathophysiology, and underlying mechanisms, but studies of its definite treatment are few. Here, we report on a 69-year-old male with heterogenous pathological presentations of SMARCA4-deficient non-small cell carcinoma. He initially presented with neck lymphadenopathies. Immunohistochemistry staining and genomic profiling confirmed the diagnosis of SMARCA4-deficient non-small cell carcinoma. The patient responded well to immune checkpoint inhibitors with nivolumab. However, new lesions with various pathological presentations and various responses to nivolumab appeared during the treatment course. The patient survived more than 3 years from the initial diagnosis. This case shows the efficacy of nivolumab to treat SMARCA4-deficient non-small cell lung carcinoma. |
| 關聯: | Frontiers in Immunology, v.14, Article 1131448 |
| 顯示於類別: | [藥學系(所)] 期刊論文
|
文件中的檔案:
| 檔案 |
描述 |
大小 | 格式 | 瀏覽次數 |
|---|
| fimmu.2023.1131448.pdf | | 2237Kb | Adobe PDF | 69 | 檢視/開啟 | | index.html | | 0Kb | HTML | 106 | 檢視/開啟 |
|
在CNU IR中所有的資料項目都受到原著作權保護.
|
